Señales en vivo de DBVT | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 abr 2024 @ 16:00):

Stats
Volumen de hoy	41 555.00
Volumen promedio	54 452.00
Capitalización de mercado	131.23M
EPS	$0 ( 2024-03-07 )
Próxima fecha de ganancias	( $-0.220 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.790
ATR14	$0.0100 (1.47%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-08	Tasse Daniel	Buy	17 094	Ordinary Shares
2024-02-06	Ndu Adora	Buy	1 825	Ordinary Shares
2023-11-22	Mohideen Pharis	Sell	2 245	Ordinary Shares
2023-11-20	Boucinha Virginie	Buy	113 000	Employee Stock Option (right to buy)
2023-11-20	Boucinha Virginie	Buy	19 000	Ordinary Shares

INSIDER POWER
99.86
Last 57 transactions
Buy: 29 162 445 \| Sell: 1 080 406

DBV Technologies S.A. Correlación

10 Correlaciones Más Positivas
PLPC	0.902
GPOR	0.891
MCAA	0.89
ENTF	0.887
MLAI	0.886
PPYA	0.884
AHRN	0.883
FRSG	0.882
ACQR	0.88
FTAA	0.88

10 Correlaciones Más Negativas
INCY	-0.916
SRTS	-0.904
FARO	-0.897
BXRX	-0.896
NWL	-0.895
CDXS	-0.892
NURO	-0.888
AYTU	-0.888
RCKY	-0.886
SBAC	-0.88

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

DBV Technologies S.A. Finanzas

Annual	2023
Ingresos:	$15.73M
Beneficio Bruto:	$20.23M (128.59 %)
EPS:	$-0.380

FY	2023
Ingresos:	$15.73M
Beneficio Bruto:	$20.23M (128.59 %)
EPS:	$-0.380

FY	2022
Ingresos:	$4.80M
Beneficio Bruto:	$-16.53M (-344.46 %)
EPS:	$-0.620

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-0.890

Financial Reports:

No articles found.

DBV Technologies S.A.

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Actualizaciones en tiempo real para DBV Technologies S.A. [DBVT]

Upcoming Earnings Alert